Evotec's Strategic Overhaul Faces Investor Scrutiny

Evotec appoints industry veteran Dieter Weinand as Chairman ahead of final 2025 results. The firm's 'Horizon' restructuring aims to boost profitability amid cautious 2026 revenue guidance.

Today's release of final annual results by Hamburg-based drug discovery firm Evotec will be scrutinized by a market already reacting to a significant governance shift. The company's ongoing "Horizon" restructuring plan is now under the guidance of a newly appointed industry veteran, a move announced just one day prior to the financial disclosure.

A Seasoned Hand at the Helm

In a strategic play to bolster its supervisory board, Evotec has nominated Dieter Weinand as its new Chairman. He is set to succeed Prof. Dr. Iris Löw-Friedrich when her term concludes in June. Weinand, a former board member at Bayer AG with a career that includes senior roles at pharmaceutical giants Pfizer and Sanofi, brings considerable commercial expertise. Market observers interpret this appointment as a deliberate effort to strengthen strategic partnerships and enhance operational effectiveness during a period of profound corporate transformation.

Restructuring Meets Cautious Guidance

While the leadership change signals intent, Evotec's executive team must now demonstrate tangible progress on its operational turnaround. The "Horizon" efficiency initiative is central to restoring profitability following a challenging 2025. Preliminary key figures underscore the scale of the task:

• 2025 Revenue: Approximately €788 million (Previous Year: €797 million)
• 2025 Adjusted EBITDA: Approximately €41 million (Previous Year: €22.5 million)
• Biologics Division: Revenue growth of roughly 40% to €259 million

Investor skepticism is palpable in the equity's recent performance. Closing at €4.47 on Tuesday, the shares have declined approximately 19% since the start of the year and trade a mere eight percent above their 52-week low. The stock's oversold condition, indicated by a Relative Strength Index (RSI) of 29.4, highlights persistent weakness. This caution is fueled in part by management's conservative 2026 revenue guidance of €700 to €780 million, which even at its upper bound falls short of 2025's projected turnover.

Consequently, during today's 14:00 CET webcast, company leadership faces pressure to provide concrete evidence on how the "Horizon" measures will achieve their full impact in the second half of the year. For the medium term, Evotec reaffirms its targets of 8-12% annual revenue growth and adjusted EBITDA margins exceeding 20%. Meeting these goals, against the backdrop of current forecasts, will require a substantial acceleration in business performance.